Advertisement
Screener

Codiak BioSciences, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

Codiak BioSciences, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

Codiak BioSciences, Inc. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$34.08 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.

Discontinued › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2022-11-03

  • Codiak BioSciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-09-30 was -$19.28M.
  • Codiak BioSciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-06-30 was -$6.78M.
  • Codiak BioSciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was -$8.03M.
  • Codiak BioSciences, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-12-31 was $16.66M.
  • Codiak BioSciences, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$37.16M.
  • Codiak BioSciences, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$91.67M.
  • Codiak BioSciences, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$77.96M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month
2022-09-30-$19.28M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
-$26.05M
derived: sum of 2 quarters · filed 2022-11-03
-$34.08M
10-Q · filed 2022-11-03
-$17.42M
derived: sum of 4 quarters · filed 2022-11-03
2022-06-30-$6.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$14.80M
10-Q · filed 2022-08-04
$1.86M
derived: sum of 3 quarters · filed 2022-08-04
-$19.84M
derived: sum of 4 quarters · filed 2022-11-03
2022-03-31-$8.03M
10-Q · filed 2022-05-05
$8.63M
derived: sum of 2 quarters · filed 2022-05-05
-$13.07M
derived: sum of 3 quarters · filed 2022-11-03
-$34.88M
derived: sum of 4 quarters · filed 2022-11-03
2021-12-31$16.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10
-$5.04M
derived: sum of 2 quarters · filed 2022-11-03
-$26.85M
derived: sum of 3 quarters · filed 2022-11-03
-$37.16M
10-K · filed 2022-03-10
2021-09-30-$21.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
-$43.51M
derived: sum of 2 quarters · filed 2022-11-03
-$53.82M
10-Q · filed 2022-11-03
-$71.78M
derived: sum of 4 quarters · filed 2022-11-03
2021-06-30-$21.81M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$32.12M
10-Q · filed 2022-08-04
-$50.07M
derived: sum of 3 quarters · filed 2022-08-04
-$85.37M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31-$10.31M
10-Q · filed 2022-05-05
-$28.27M
derived: sum of 2 quarters · filed 2022-05-05
-$63.56M
derived: sum of 3 quarters · filed 2022-05-05
-$79.47M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31-$17.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10
-$53.25M
derived: sum of 2 quarters · filed 2022-03-10
-$69.16M
derived: sum of 3 quarters · filed 2022-03-10
-$91.67M
10-K · filed 2022-03-10
2020-09-30-$35.29M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
-$51.21M
derived: sum of 2 quarters · filed 2021-11-04
-$73.71M
10-Q · filed 2021-11-04
-$95.35M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30-$15.91M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
-$38.41M
10-Q · filed 2021-08-05
-$60.05M
derived: sum of 3 quarters · filed 2021-08-05
2020-03-31-$22.50M
10-Q · filed 2021-05-06
-$44.14M
derived: sum of 2 quarters · filed 2021-05-06
2019-12-31-$21.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-17
-$77.96M
10-K · filed 2021-03-17
2019-09-30-$56.32M
10-Q · filed 2020-11-19